Safety and efficacy of glecaprevir/pibrentasvir combination therapy for hemodialysis patients with genotype 2 hepatitis C infectio

Not Applicable

• Conditions: HD patients with GT2 HCV infection

• Registration Number: JPRN-UMIN000036099
• Lead Sponsor: Hokkaido University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-06
• Study Completion: 2021-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1 Patients with a past history of hypersensitivity to HCV protease inhibitors and NS5A inhibitors 2 Patients with serious liver dysfunction (Child-Pugh Class B or C) 3 Patients with difficult-to-control heart disease (e.g., myocardial infarction, heart failure, and arrhythmia) 4 Patients who have malignant tumors, including hepatoma, at the start of treatment 5 Patients on treatment with drugs listed in the contraindications for coadministration in the package insert (e.g., some antifungals, some antiepileptics, and human immunodeficiency virus (HIV) protease inhibitors) 6 Other patients judged to be inappropriate to participate in the study by the primary physician

Study & Design

• Study Type: Observational
• Study Design: Not specified